Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Obeticholic Acid in Nonalcoholic Steatohepatitis (REGENERATE-like)
2015-002560-16Phase 3Unknown
- Sponsor
- Intercept Pharmaceuticals
- Start
- Oct 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Obeticholic acid with Placebo (2 arms). Primary endpoint: Primary Objective at Month 18 Interim Analysis. Status: unknown.
02
Drugs
obeticholic acid
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2015-002560-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002560-16.